Teriparatide (recombinant human parathyroid hormone [1-34]) increases foot bone remodeling in diabetic chronic Charcot neuroarthropathy: a randomized double-blind placebo-controlled study

What Was Tested

Researchers studied Teriparatide and Parathyroid Hormone (PTH 1-84) in this randomized controlled trial publication.

Who Took Part

By PubMed's age tags, the people studied were middle-aged adults, both men and women.

Thirty-eight patients were screened and data were analyzed for 20.

How the Study Was Run

The researchers set it up as a randomized, double-blind and placebo-controlled study.

The participants were allocated by chance, so the Teriparatide group and the comparison group should start out alike.

Blinding on both sides kept the participants and researchers unaware of who received Teriparatide.

The comparison arm used a placebo, so changes seen with Teriparatide could be set against what happens without it.

The maximum standardized uptake (SUVmax ) value of 18 F-FDG PET/CT the region of interest, bone turnover markers and foot bone mineral density BMD were determined.

The primary outcome measure was change in SUVmax g/ml.

What Was Measured

The subject headings attached to it are Arthropathy, Neurogenic, Bone Density Conservation Agents, Bone Remodeling, Chronic Disease, Diabetic Neuropathies, Fractures, Bone and Prognosis.

Author keywords: Charcot neuroarthropathy, bone mineral density, bone turnover markers, diabetic foot, teriparatide and 夏科神经关节病.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Teriparatide and Parathyroid Hormone (PTH 1-84).

The abstract goes on to report its results in about 6 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2019 (Journal of diabetes), a journal based in Australia.

More context: the Teriparatide compound page and the Parathyroid Hormone (PTH 1-84) compound page, all human trials.